Answers are grounded in this paper and cite their sources.
In a subpopulation analysis of patients from phase 3 trials with moderate-to-severe non-pustular palmoplantar involvement and moderate-to-severe plaque psoriasis, ixekizumab treatment resulted in greater and more rapid improvements than placebo and etanercept at week 12; improvements were sustained with continued treatment.
No takes yet. Share an insight, caveat, or question.
Menter et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: